Marinomed Biotech has announced that it signed a distribution agreement with Perrigo for its Carragelose iota-carrageenan nasal spray, and Perrigo has already launched the product in Finland, Norway, Sweden and France. The OTC nasal spray is being marketed for the prevention of respiratory viruses under the name Physiomer in the Scandinavian countries and as Phytosun Aroms in France.
In July 2021, Marinomed announced that M8 Pharmaceuticals had acquired the rights to Carragelose nasal spray in Brazil and Mexico. Nasal sprays that include Carragelose are now available in numerous countries, including Italy, Austria, Canada, China, and Australia.
Marinomed CEO Andreas Grassauer commented, “We are proud to partner with Perrigo, an exceptionally experienced organization, to further extend the global reach of our virus blocker Carragelose. With the likely resurgence of respiratory diseases in the upcoming cold season, we are satisfied that Carragelose will be available to even more people providing them protection from viral respiratory infections. The virus-blocking properties of Carragelose can make an important contribution to improving public health and to support hygiene measures against respiratory viruses.”
Perrigo VP International R&D and Innovation Anneleen Spooren said, “Marinomed has shown impressive data on the potential of Carragelose for prevention and self-medication of respiratory infections caused by multiple viruses. Carragelose provides an extremely good fit with our portfolio of effective self-care products. We are happy to now expand our portfolio with this clinically validated virus-blocking and hypertonic product that can provide a fast relief of the symptoms. We are convinced that with Marinomed, we have a strong and reliable science-based partner at our side.”
Read the Marinomed Biotech press release.
